CN103202868B - Composition for preventing and treating flu as well as preparation method and application thereof - Google Patents
Composition for preventing and treating flu as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN103202868B CN103202868B CN201310113838.7A CN201310113838A CN103202868B CN 103202868 B CN103202868 B CN 103202868B CN 201310113838 A CN201310113838 A CN 201310113838A CN 103202868 B CN103202868 B CN 103202868B
- Authority
- CN
- China
- Prior art keywords
- parts
- influenza
- preventing
- radix
- qiang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a composition for preventing and treating flu as well as a preparation method and an application thereof. The composition comprises the following components in parts by mass: 10 to 20 parts of bupleurum, 10 to 15 parts of libanotis buchtormensis, 10 to 15 parts of artemisia rupestris and 10 to 15 parts of Taiqiang. With the aid of 'Qinling forest herb resource protection and development and utilization technology research thereof' of a special scientific research item in the public forestry welfare industry of State Forestry Bureau, the anti-flu Chinese medicinal preparation consisting of four special Chinese medicinal herbs in Mount Taibai of Qinling and using the bupleurum as a monarch is prepared. Pharmacodynamic animal experiments, acute toxicity experiments and long-term toxicity experiments for pharmacodynamic treatment effect evaluation and toxicity safety evaluation verify that the composition has a remarkable treatment effect of treating flu virus infection, particularly cold caused by H1N1 flu viruses, and is safe and nontoxic.
Description
Technical field
The invention belongs to Chinese herb prevention influenza technical field, relate to a kind of compositions and formulation preparation method and application that prevents and treats influenza.
Background technology
Influenza (Influenza) is a kind of Acute respiratory infectious disease being caused by influenza virus, and infectiousness is strong, and sickness rate is high.4 large-scale influenza virus of eighties of last century have attacked the mankind, bring very grave disaster.Enter after new century, H5N1 Human avian flu virus and influenza A H1N1 influenza virus popular, brings great harm to the mankind.In recent years influenza have Epidemic Scope wide, propagate fast, the cycle is long, the easy feature such as recurrence after drug withdrawal, to control, has brought huge difficulty.Safety, efficient Tamiflu receive much concern in medical circle.
Up to now, the major measure that influenza virus is resisted in the whole world still be take vaccination and use antiviral drugs as main.Because surface antigen hemagglutinin HA and the neuraminidase NA of influenza virus easily morphs, cause the preventive effect of vaccine to reduce.Therefore, the use of antiviral drugs remains the main selection of morbidity crowd prevention and control influenza.China approximately has 8.4 hundred million people need take Tamiflu every year, and effectively Tamiflu research and development have Great significance.
Current Tamiflu has chemicals, Chinese patent medicine, Chinese medicine etc.Chemicals (as oseltamivir phosphate capsule, amantadine etc.) is expensive, easily produces drug resistance, is difficult to control the popular of influenza.The Chinese patent medicine of clinical treatment influenza, because formula is fixing, often can not show flexible and changeablely as decoct side's medicine, with disease plus-minus, makes the practical application of Chinese patent medicine be subject to certain restriction.China has seasonal influenza to occur every year.Chinese Traditional Medicine, owing to adopting multi-medicament compatibility to form, has safe, efficient, many target spots, is difficult for producing the advantages such as drug resistance, aspect treatment influenza, has irreplaceable advantage.
Summary of the invention
The problem that the present invention solves is to provide a kind of compositions and formulation preparation method and application that prevents and treats human influenza, and said composition compatibility is proper, and prescription is rigorous, has simultaneously using both cold and hot drugs, the effect of coordination between ascending and descending, and safety non-toxic, can be applicable to the control of influenza.
The present invention is achieved through the following technical solutions:
Prevent and treat a compositions for influenza, in mass fraction, comprise following component:
10～20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 10～15 parts of Herba Achilleaes, too Qiang is 10～15 parts.
Further, in mass fraction, comprise following component:
20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 10～15 parts of Herba Achilleaes, too Qiang is 10～15 parts.
In mass fraction, comprise following component:
20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 10～12 parts of Herba Achilleaes, too Qiang is 12～15 parts.
Further, in mass fraction, comprise following component:
20 parts of Radix Bupleuri, 10 parts of Radix Libanotidis buchotomensis, 12 parts of Herba Achilleaes, too Qiang is 15 parts.
The effective ingredient of the described compositions of preventing and treating influenza is that Radix Bupleuri, Radix Libanotidis buchotomensis, Herba Achilleae He Tai Qiang are first used to cold water soak 2～4h after pulverizing, and then decocts and extracts at least 30min, filters the fried liquid of gained.
A preparation method of preventing and treating the Chinese medicine preparation of influenza, comprises the following steps:
1), according to following mass fraction meter, by after 10～20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 10～15 parts of pulverizing of Herba Achilleae 10～15Fen Hetai Qiang, add the cold water soak 1～2h that is equivalent to 5～8 times of medical material amounts;
2) after immersion finishes, boil 30～60min, filter; Medicinal residues add 3～5 times of quality water and again decoct 20～40min, filter;
3) merge twice fried liquid, in water-bath, be concentrated into extractum.
Describedly also using prepared extractum as effective ingredient, add adjuvant and make decoct, pill, tablet or capsule.
The described compositions of preventing and treating influenza is prevented and treated the application in the medicine of influenza in preparation.
Described medicine has resisiting influenza virus and improves the effect of immunity of organisms.
The described compositions of preventing and treating influenza is applied in the medicine of preparation control influenza infection.
Compared with prior art, the present invention has following useful technique effect:
Compositions and the formulation preparation method thereof of preventing and treating influenza provided by the invention, optimizes characteristic Chinese herbal medicine in four Mount Taibais, the taste Qinling Mountains and forms and take the influenza Chinese medicinal formulae that Radix Bupleuri is monarch drug.By animal pharmacodynamics test, acute toxinology experiment and long-term toxicological test, carry out pharmacodynamics therapeutic evaluation and toxicological assessment, confirm this prescription at treatment influenza infection, the flu that particularly H1N1 influenza virus causes has significant curative effect, safety non-toxic.
The present invention is subsidized by State Administration of Forestry's forestry public welfare industry scientific research special " Qinling Mountains woods medicine protection of resources and evaluation and exploration technology research thereof "; traditional Chinese medicine theory is combined with modern science and technology; in animal body on the basis of experiment; the inhibitory action of each compatibility group infected by influenza of characteristic Chinese herbal medicine in research Mount Taibai, the Qinling Mountains; filter out optimal drug compatibility, for clinical application provides theoretical foundation.Disclosed the science and the preciseness that use this prescription treatment influenza, the Chinese herbal medicine in prescription all comes from China's Qinling Mountain Areas characteristic woods medicine simultaneously, for excavating Mount Taibai, Qinling Mountains Chinese herbal medicine resource, has great importance.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is described in further detail, and the explanation of the invention is not limited.
The present invention sums up the experience of Shaanxi Province's Mount Taibai district medication among the people, optimizes characteristic Chinese herbal medicine in four Mount Taibais, the taste Qinling Mountains and forms and take the influenza Chinese medicinal formulae that Radix Bupleuri is monarch drug.By pharmacodynamics animal experiment, acute toxinology experiment and long-term toxicological test, carry out pharmacodynamics therapeutic evaluation and toxicological assessment, confirm this prescription at treatment influenza infection, the flu that particularly H1N1 influenza virus causes has significant curative effect, safety non-toxic.
It is monarch drug that prescription of the present invention be take Radix Bupleuri (Radix Bupleuri), by Radix Bupleuri (Radix Bupleuri), Radix Libanotidis buchotomensis (Libanotis spodotrichoma K.T.Fu), Herba Achilleae (Alpine Yarrow Herb) He Tai Qiang (Rhizoma et Radix Notopterygii), formed its weight proportion following (60kg be grown up clinical plan dosage):
Radix Bupleuri has that expelling pathogenic factors from the exterior expels the heat-evil, the effect of dispersing the stagnated live-QI to relieve the stagnation of QI, elevate a turnable ladder yang-energy, cures mainly cold, fever, alternate attack of chill and fever, malaria, the diseases such as stagnation of QI due to depression of the liver.Modern pharmacology result of study shows: the polysaccharide component in Radix Bupleuri can strengthen the function of phagocyte and natural killer cell, improves special viral antibody titre, thereby improves the immunologic function of human body.
Radix Libanotidis buchotomensis is one of Shaanxi " "Taibai Qiyao" ", and the sweet temperature of this moral character, bitter in the mouth, have expelling wind and cold, expelling wind and removing dampness, and the effect of activating collaterals to relieve pain, for anemofrigid cold, general aching, arthroncus, traumatic injury, the treatment of the diseases such as rheumatism bones and muscles pain.
Herba Achilleae has the effect of expelling pathogenic wind from the body surface, promoting blood circulation to remove blood stasis, cures mainly anemofrigid cold, traumatic injury congestive edema, shows the clinical various Acute and chronic inflammations that are used for treating.
Qiang's one medicine too, can relieving the exterior syndrome by diaphoresis, again can wind-damp dispelling and pain relieving.According to clinical practical experiences in recent years, the effect that this medicine is brought down a fever is fine, can coordinate other antiviral Chinese herbal treatment wind heat table diseases.
The effects such as the influenza of above-mentioned each taste Chinese medicine, antipyretic, analgesia, antiinflammatory all have research, but there is no people as prescription, use.The compatibility of medicines in a prescription of the present invention is proper, and prescription is rigorous, has simultaneously using both cold and hot drugs, and the effect of coordination between ascending and descending is used prescription treatment influenza of the present invention to have in theory feasibility.Further using H1N1 influenza infection mice as evaluating drug effect model; by indexs such as infecting mouse survival rate, survival natural law, lungs index, the variations of Antibody of Influenza titre; having evaluated prescription of the present invention has significant protective effect to H1N1 influenza infection mice, for the clinical treatment of influenza provides certain support.
Provide some concrete prescription embodiment below.
Embodiment 1
This example needed raw material medicine is Radix Bupleuri 20g, Radix Libanotidis buchotomensis 10g, Herba Achilleae 12g, the too 15g of Qiang.
Embodiment 2
This example needed raw material medicine is Radix Bupleuri 20g, Radix Libanotidis buchotomensis 10g, Herba Achilleae 15g, the too 12g of Qiang.
Embodiment 3
This example needed raw material medicine is Radix Bupleuri 20g, Radix Libanotidis buchotomensis 15g, Herba Achilleae 10g, the too 12g of Qiang.
Embodiment 4
This example needed raw material medicine is Radix Bupleuri 20g, Radix Libanotidis buchotomensis 15g, Herba Achilleae 12g, the too 10g of Qiang.
Embodiment 5
This example needed raw material medicine is Radix Bupleuri 20g, Radix Libanotidis buchotomensis 12g, Herba Achilleae 15g, the too 10g of Qiang.
Embodiment 6
This example needed raw material medicine is Radix Bupleuri 20g, Radix Libanotidis buchotomensis 12g, Herba Achilleae 10g, the too 15g of Qiang.
Embodiment 7
This example needed raw material medicine is Radix Bupleuri 15g, Radix Libanotidis buchotomensis 12g, Herba Achilleae 10g, the too 10g of Qiang.
Embodiment 8
This example needed raw material medicine is Radix Bupleuri 10g, Radix Libanotidis buchotomensis 10g, Herba Achilleae 10g, the too 10g of Qiang.
The preparation technology of above embodiment is as follows:
After four Chinese medicine is pulverized, accurately weigh and put in decoction container, decoct container and take crock, marmite as good, add the cold water soak 2h that is equivalent to 5～8 times of medical material amounts, boil 30～60min, filter; Medicinal residues add 3～5 times of water gagings to be continued to decoct, and boils 20～40min, filters.Merge fried liquid twice, in water-bath, be concentrated into the water decoction that every 1ml is equivalent to medical material amount 1～2g.
Above-mentioned Chinese medicinal formulae, can utilize general pharmaceutical technology (tcd) and equipment to make different dosage form: water decoction, pill, tablet and capsule etc., can meet different sick human needs.
Provide zoopery below.
By pharmacodynamics animal experiment, to 8 embodiment gained water decoctions of prescription of the present invention are carried out to influenza therapeutic evaluation, and further screen optimal drug compatibility; By acute toxinology experiment and long-term toxicological test, verify the safety of this prescription.
Pharmacodynamics test
1, experiment material
1.1 animal
340 of BALB/c mouse, SPF level, body weight (13 ± 2) g, male and female half and half, are provided by Xi'an Jiaotong University Medical College's Experimental Animal Center, the animal quality certification number: SCXK(Shan) 2007-001.
1.2 Strain
H1Nl strains of influenza viruses A/swine/Shaanxi/sf/2011 (H1N1), GenBank serial number: JX860700.1, is H1Nl influenza virus Local Isolates.Above-mentioned Strain is rised in value in mdck cell and Embryo Gallus domesticus, and HA test records virus titer and reaches 8Log2, and-80 ℃ frozen standby.
1.3 medicines and reagent
Prescription is comprised of Radix Bupleuri, Radix Libanotidis buchotomensis, Herba Achilleae He Tai Qiang, all at favorable season, plucks from Mount Taibai, the Qinling Mountains, in dry ventilation, naturally dries in the shade, and preserves.The body surface area computing method of introducing in < < herbal pharmacology experimental methodology > > with reference to Li Yikui chief editor, people's dosage is converted into the dose,equivalent of BALB/c mouse, prepare water decoction, high pressure steam sterilization (110 ℃, 15min), 4 ℃ of preservations, standby;
Oseltamivir phosphate capsule (Tamiflu, oseltamivir phosphate capsule): Basel, SUI Hao Fumai Roche company limited product, Shanghai company limited of Roche Group subpackage, lot number B1162, lot number of the repackaged products SH0033.
1.4 instrument
TGL-19 table-type high-speed refrigerated centrifuge (ShangHai City centrifugal Machine Institute product); Electric heating constant-temperature water-bath tank (Shanghai Fang Rui instrument plant product); MP2000D electronic balance (Shanghai Hengping Science Instrument Co., Ltd.'s product); IVC mice rearging cage, Suzhou teaching Long Ju factory product.
2, experimental technique
The impact of Antibody of Influenza level, lung index in 2.1 prescription influenza virus infected body weight of the present invention, serum
Get 132 BALB/c mouse, be divided at random 11 groups, be respectively blank group, model group, oseltamivir phosphate capsule-positive drug matched group and each embodiment group, 12 every group.Except blank group, mice is slightly anaesthetized with ether, with 15 LD
50h1N1 influenza virus collunarium infect, every 35uL.Infect and started administration the same day, continuous 5d, blank group and model group are filled with and are fed equal-volume distilled water.Observe mice existence and active situation every day and weigh, within the 6th day, plucking eyeball and get blood and prepare serum, Antibody of Influenza level in HI test determination serum.Dissect mice, claim lung quality, calculate lung index and lung index.
Lung index=lung wet weight (g)/body weight (g)
The impact of 2.2 prescription influenza virus infected pulmonary inflammation model mortality rates of the present invention, time-to-live and increase in life span
Get 200 BALB/c mouse, be divided at random 10 groups, be respectively model group, oseltamivir phosphate capsule-positive drug matched group and each embodiment group, 20 every group.Each is organized mice and slightly anaesthetizes with ether, with 15 LD
50influenza virus drop nose infects, every 35uL.Infect and started administration the same day, continuous 5d, model group is filled with and is fed equal-volume distilled water.The death condition of animals in 2 weeks after observe infecting, calculating mortality rate, on average survive natural law and increase in life span.
2.3 date processing
All data all with
represent, group difference carries out one factor analysis of variance with SPSS20.0 statistics software.
3, result
The impact of 3.1 prescription influenza virus infected body weight of the present invention
As can be seen from Table 1: model group and each test group mice body weight after influenza virus infection all declines to some extent, after prescription treatment of the present invention, each test group Mouse Weight level is progressively gone up, and wherein mono-group of weight of mice of embodiment is the most obvious.After treatment finishes, each test group Mouse Weight is compared with model group: mono-, two, three, five, six, seven, eight groups of embodiment and oseltamivir phosphate capsule group inequality heteropole be (P ﹤ 0.01) significantly, and embodiment tetra-significant differences (P ﹤ 0.05).Above result of the test prompting: prescription of the present invention has certain effect for the body weight gain of protection influenza model mice.
The impact of table 1 prescription of the present invention on influenza model mice body weight
Note: 1) with the comparison of blank group: * represents P ﹤ 0.05, and * * represents P ﹤ 0.01, and * * * represents P ﹥ 0.05;
2) represent P ﹤ 0.05 with model group comparison: A, B represents P ﹤ 0.01.
The impact of Antibody of Influenza level in 3.2 prescription influenza virus infected serum of the present invention
As can be seen from Table 2: prescription of the present invention can improve after influenza infection Antibody of Influenza level in mice serum, points out prescription of the present invention to have potentiation to the immune protective efficiency of mice.
The impact of Antibody of Influenza level in table 2 influenza virus infected serum
The impact of 3.3 prescription influenza virus infected lung indexes of the present invention
As can be seen from Table 3: adopt after H1N1 influenza infection BALB/c mouse, the lung index of mice obviously increases.After prescription treatment 5d of the present invention, each embodiment group and oseltamivir phosphate capsule group mouse lung index all have reduction in various degree, compare inequality heteropole significantly (P ﹤ 0.01) with model group, and wherein that the biggest drop is mono-group of embodiment.
The impact of table 3 prescription influenza virus infected of the present invention lung index
Note: with model group comparison: 1 represents that P ﹤ 0.05,2 represents P ﹤ 0.01.
The impact of 3.4 prescription influenza virus infected mortality rates of the present invention
As can be seen from Table 4: adopt after HlNl influenza infection mice 14d, mouse death rate is 90%, and the natural law of on average surviving is 7.97d; Take each embodiment gained water decoction of prescription of the present invention after 5 days, dead mouse number obviously reduces, and mortality rate all obviously declines; Each embodiment group all can extend the animal natural law of on average surviving, with the poor heteropole of model group significantly (P<0.01).
Table 4 prescription influenza virus infected of the present invention mortality rate, the impact of time-to-live
Note: represent P ﹤ 0.05 with model group comparison: *, * * represents P ﹤ 0.01.
4, conclusion
Each embodiment gained water decoction of prescription of the present invention can obviously reduce mice after H1N1 influenza infection lung index, reduce mortality rate, extend the time-to-live, can maintain Mouse Weight steady growth after influenza infection simultaneously.In addition, prescription of the present invention can improve after influenza infection Antibody of Influenza level in mice serum.Above result of the test prompting: the viral animal model of epidemic catarrh that prescription of the present invention causes HlNl influenza infection mice has remarkable therapeutical effect, and what wherein action effect was best is embodiment mono-gained water decoction.
Acute toxinology experiment
Known according to above therapeutic test result, the action effect that the resisiting influenza virus of prescription embodiment mono-of the present invention infects is best, and it is carried out to acute toxinology experiment, checks the safety of this prescription.Process of the test and result are as follows:
Because trial test does not measure the LD of recipe drug
50, only do maximum dosage-feeding experiment.With the maximum that can make, can fill with concentration (4.5g/ml), the maximum gavage capacity of mice (0.4ml/20g) gavages medicine twice altogether through stomach, and wherein gavage volume reduces by half for the second time.
Result: dead mouse situation, does not appear in mice outward appearance, behavioral activity, breathing, secretions, Excreta no abnormality seen after gavage.Record maximum tolerated dose >=135g/kg, this dosage is adult's (calculating with 60kg) the more than 409 times of dosage 0.33g/kg for clinical plan.According to acute toxicity grading criteria, think this tested medicine to animal subject without acute toxicity.
Long-term toxicological test
Prescription embodiment mono-gained water decoction of the present invention is carried out to long-term toxicological test, by, high dose gavage long-term to SD rat, observe its clinical response.Test divides 4 groups: blank group, 12.5 times of people's pharmaceutical quantities groups, 25 times of people's pharmaceutical quantities groups and 50 times of people's pharmaceutical quantities groups, blank group gives equal-volume distilled water.Every day gavage once, continuous 90 days.
Result: the indexs such as the body weight gain level of each administration group SD rat, organ index, routine blood test, liver function, renal function, myocardial enzymes are compared there was no significant difference (P > 0.05) with blank group, main organs histopathologic examination is also without pathological change.
Conclusion: prescription safety non-toxic of the present invention generally can not produce untoward reaction under clinical dosage.
Claims (10)
1. a compositions of preventing and treating influenza, is characterized in that, in mass fraction, following component, consists of:
10～20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 10～15 parts of Herba Achilleae 10～15Fen Hetai Qiang.
2. compositions of preventing and treating influenza as claimed in claim 1, is characterized in that, in mass fraction, following component, consists of:
20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 10～15 parts of Herba Achilleae 10～15Fen Hetai Qiang.
3. compositions of preventing and treating influenza as claimed in claim 1, is characterized in that, in mass fraction, following component, consists of:
20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 12～15 parts of Herba Achilleae 10～12Fen Hetai Qiang.
4. compositions of preventing and treating influenza as claimed in claim 1, is characterized in that, in mass fraction, following component, consists of:
20 parts of Radix Bupleuri, 10 parts of Radix Libanotidis buchotomensis, 15 parts of Herba Achilleae 12Fen Hetai Qiang.
5. compositions of preventing and treating influenza as claimed in claim 1, is characterized in that, the effective ingredient of said composition is that Radix Bupleuri, Radix Libanotidis buchotomensis, Herba Achilleae He Tai Qiang are first used to cold water soak after pulverizing, and then decocts and extracts at least 30min, filters the fried liquid of gained.
6. a preparation method of preventing and treating the Chinese medicine preparation of influenza, is characterized in that, comprises the following steps:
1), according to following mass fraction meter, by after 10～20 parts of Radix Bupleuri, 10～15 parts of Radix Libanotidis buchotomensis, 10～15 parts of pulverizing of Herba Achilleae 10～15Fen Hetai Qiang, add the cold water soak 1～2h that is equivalent to 5～8 times of medical material amounts;
2) after immersion finishes, boil 30～60min, filter; Medicinal residues add 3～5 times of quality water and again decoct 20～40min, filter;
3) merge twice fried liquid, in water-bath, be concentrated into extractum.
7. preparation method of preventing and treating the Chinese medicine preparation of influenza as claimed in claim 6, is characterized in that, usings prepared extractum as effective ingredient, adds adjuvant and makes decoct, pill, tablet or capsule.
8. the application of compositions of preventing and treating influenza claimed in claim 1 in the medicine of preparation control influenza virus.
9. application as claimed in claim 8, is characterized in that, described medicine is for improving the medicine of immunity.
10. the application in the medicine of the flu that compositions of preventing and treating influenza claimed in claim 1 causes preparation control influenza virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310113838.7A CN103202868B (en) | 2013-04-02 | 2013-04-02 | Composition for preventing and treating flu as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310113838.7A CN103202868B (en) | 2013-04-02 | 2013-04-02 | Composition for preventing and treating flu as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103202868A CN103202868A (en) | 2013-07-17 |
| CN103202868B true CN103202868B (en) | 2014-11-26 |
Family
ID=48750422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310113838.7A Expired - Fee Related CN103202868B (en) | 2013-04-02 | 2013-04-02 | Composition for preventing and treating flu as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103202868B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768084A (en) * | 2014-01-24 | 2014-05-07 | 华南农业大学 | Application of saikosaponin a in preparing medicaments for preventing and treating influenza in human and animals |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125167A (en) * | 2006-08-17 | 2008-02-20 | 王玉怀 | Medicine for treating influenza |
| CN101829185A (en) * | 2010-06-02 | 2010-09-15 | 赵敬民 | Medicinal composition for resisting influenza virus |
-
2013
- 2013-04-02 CN CN201310113838.7A patent/CN103202868B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125167A (en) * | 2006-08-17 | 2008-02-20 | 王玉怀 | Medicine for treating influenza |
| CN101829185A (en) * | 2010-06-02 | 2010-09-15 | 赵敬民 | Medicinal composition for resisting influenza virus |
Non-Patent Citations (4)
| Title |
|---|
| 一枝蒿化学成份及临床应用研究进展;梁永红等;《新疆中医药》;20090131;第27卷(第1期);第75页左栏第1段 * |
| 柴胡-防治感冒之良药;蒲昭和;《求医问药》;20070430(第4期);第47页左栏第1-2段和右栏最后一段 * |
| 梁永红等.一枝蒿化学成份及临床应用研究进展.《新疆中医药》.2009,第27卷(第1期),第75-77页. * |
| 蒲昭和.柴胡-防治感冒之良药.《求医问药》.2007,(第4期),第47页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103202868A (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727686B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN102085311B (en) | Traditional Chinese medicinal composition for preventing or treating common cold and/or flu, method for preparing same and application thereof | |
| US20230040479A1 (en) | Fructus forsythiae and radix astragali compound preparation, and preparation method therefor and use thereof | |
| CN103202868B (en) | Composition for preventing and treating flu as well as preparation method and application thereof | |
| CN101569700B (en) | application of Chinese medicinal drug in preparing medicine to treating avian influenza | |
| CN103550596A (en) | Application of Anerning granules in preparing medicament for treating viral pneumonia | |
| CN104983968A (en) | Pyretolysis traditional Chinese medicine composition and preparation method | |
| CN105434631A (en) | Application of zanthoxylum oil in preparing drugs or health-care products for preventing and/or treating virus flu | |
| CN106344549A (en) | Application of rhein in preparation of drugs for preventing and/or treating hand-foot-and-mouth disease | |
| CN103341026B (en) | A kind of prevent and treat influenza compositions and formulation preparation method and application | |
| CN105535135A (en) | A traditional Chinese medicine composition having an anti-influenza virus function, a preparing method thereof and uses of the composition | |
| CN106913802A (en) | A kind of Tibetan medicinal composition for viral pneumonia | |
| CN101564475A (en) | Application of Kegan Liyan Oral Liquid in preparing Chinese medicaments for preventing and treating bird flu | |
| CN104800570A (en) | Chinese herbal preparation for treating pneumonia | |
| CN109260192A (en) | Purposes of the qroxylin A in preparation prevention and treatment virus infection of respiratory system drug | |
| CN103099877B (en) | Traditional Chinese medicine formula for treating and preventing children asthmatic disease | |
| CN102389560B (en) | Traditional Chinese medicine used for treating epidemic encephalitis type B | |
| CN104815052A (en) | Chinese medicinal composition for resisting influenza virus infection and preparation method thereof | |
| CN106806871A (en) | A kind of medicine for treating influenza | |
| CN106620380A (en) | Traditional Chinese medicine feed additive for preventing and treating viral diseases in livestock and poultry and preparation method thereof | |
| CN106822818A (en) | One pharmaceutical formulation for the treatment of influenza | |
| CN106176871A (en) | A kind of Fructus Hippophae compound recipe preventing and treating influenza and preparation thereof and application | |
| CN111920920A (en) | Traditional Chinese medicine formula for preventing and treating viral pneumonia and patent medicine preparation method | |
| CN105687757A (en) | Traditional Chinese medicine composition for treating phlegm-qi stagnation type hyperthyreosis with automatic junctional tachycardia | |
| CN102600435B (en) | Device and formula of traditional Chinese medicine for stabilizing heart and relieving asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 Termination date: 20150402 |
|
| EXPY | Termination of patent right or utility model |